Main Industry
Biotechnology
Main Product/Service
ORAL PEPTIDE
Summary of development timelines-product
MIRA/JER Design
Lead Optimization
Preclinical Studies
Phase I
Phase II
Phase III
ANY002 Oral GLP1 product A: Prototype with human PK results available
ANY004 Oral GLP1 product B: Prototype in animal study
ANY003 Novel TNFα Inhibitor: Lead optimization
ANYOOX Open for collaboration
Summary of development timelines-product
MIRA/JER Design
Lead Optimization
Preclinical Studies
Phase I
Phase II
Phase III
ANY002 Oral GLP1 product A: Prototype with human PK results available
ANY004 Oral GLP1 product B: Prototype in animal study
ANY003 Novel TNFα Inhibitor: Lead optimization
ANYOOX Open for collaboration
Founded Year
2016
Unified Business No.
66262721
Status
Active
Number of Employees
15
Total Paid-in
Capital
491,015,200 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2025)
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Anya is a young, agile and innovative publicly listed (TWO: 7776) pharmaceutical company founded in Taipei, Taiwan with offices in India and the United States. Our core mission is to be the authority in oral delivery of peptides. Our patented technology platform Mira/JeR is a flexible solution easy to adapt to a large variety of peptides. Mira/JeR has shown delivery of therapeutic amount in a number of clinical and preclinical studies in a variety of peptides such as teriparatide, leuprorelin, octreotide, semaglutide, liraglutide, tirzepatide and insulin glargine.
The management team has extensive experience in the pharmaceutical industry with average 20 years in development and commercialization of biologics and small molecules.
Our guiding principles are Excellence, Engagement and Efficiency.
The management team has extensive experience in the pharmaceutical industry with average 20 years in development and commercialization of biologics and small molecules.
Our guiding principles are Excellence, Engagement and Efficiency.
